Back to search
FDAFDA · Food and drugs·Recall number D-0126-2021

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.

Published December 16, 2020 · Recall initiated: December 8, 2020

Summary

FDA records drug Class II recall D-0126-2021, published December 16, 2020 and initiated December 8, 2020. Recalling firm: Shilpa Medicare Limited; Status: Terminated; Reported quantity: 2008 vials; Lot: Lot #: 7S10185A, Exp. 10/31/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Shilpa Medicare Limited
Distributor
Nationwide in the U.S.
Lot
Lot #: 7S10185A, Exp. 10/31/2021
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08. recalled?

Yes. FDA published recall D-0126-2021 on December 16, 2020. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter